ADAPTIMMUNE THERAPEUTICS PLC's ticker is ADAP and the CUSIP is 00653A107. A total of 93 filers reported holding ADAPTIMMUNE THERAPEUTICS PLC in Q3 2021. The put-call ratio across all filers is 3.27 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $237,000 | +7.7% | 45,900 | -11.4% | 0.00% | – |
| Q2 2021 | $220,000 | +197.3% | 51,800 | +275.4% | 0.00% | – |
| Q1 2021 | $74,000 | -68.0% | 13,800 | +76.9% | 0.00% | – |
| Q4 2020 | $231,000 | +272.6% | 7,800 | 0.0% | 0.00% | – |
| Q3 2020 | $62,000 | -47.5% | 7,800 | -33.9% | 0.00% | – |
| Q2 2020 | $118,000 | +637.5% | 11,800 | +100.0% | 0.00% | – |
| Q1 2020 | $16,000 | +128.6% | 5,900 | 0.0% | 0.00% | – |
| Q4 2019 | $7,000 | – | 5,900 | +3370.6% | 0.00% | – |
| Q3 2019 | $0 | -100.0% | 170 | -91.1% | 0.00% | – |
| Q2 2019 | $8,000 | 0.0% | 1,900 | 0.0% | 0.00% | – |
| Q1 2019 | $8,000 | +60.0% | 1,900 | +100.0% | 0.00% | – |
| Q4 2018 | $5,000 | -61.5% | 950 | 0.0% | 0.00% | – |
| Q3 2018 | $13,000 | +18.2% | 950 | 0.0% | 0.00% | – |
| Q2 2018 | $11,000 | 0.0% | 950 | 0.0% | 0.00% | – |
| Q1 2018 | $11,000 | +83.3% | 950 | 0.0% | 0.00% | – |
| Q4 2017 | $6,000 | – | 950 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| MPM ASSET MANAGEMENT LLC | 6,287,101 | $4,903,939 | 2.63% |
| Syncona Portfolio Ltd | 1,377,294 | $1,074,289 | 1.60% |
| MPM BioImpact LLC | 5,095,912 | $3,974,811 | 1.06% |
| NEA Management Company, LLC | 17,079,778 | $13,322,227 | 1.03% |
| TANG CAPITAL MANAGEMENT LLC | 5,166,954 | $4,030,224 | 0.57% |
| PFM Health Sciences, LP | 10,423,135 | $8,130,045 | 0.38% |
| Matrix Capital Management Company, LP | 38,974,185 | $30,399,864 | 0.36% |
| Long Focus Capital Management, LLC | 10,963,158 | $8,551,263 | 0.31% |
| Acuitas Investments, LLC | 479,764 | $374,216 | 0.22% |
| Endurant Capital Management LP | 311,944 | $243,316 | 0.22% |